StreetAlpha.app
Home › Stocks › MNKD

Mannkind Corp (MNKD)

Healthcare
Members
LATEST PRICE

MannKind develops and sells inhaled and wearable treatments for diabetes, heart failure and lung conditions. MNKD reports earnings on Thu, Nov 5, 2026. Analyst consensus is Strong Buy, based on the latest ratings from 4 firms (4 buy, 0 hold, 0 sell).

Prices, price targets and earnings estimates for MNKD are shown to AI Starter and AI Pro members. Ratings, flow and news are open to everyone.See plans
AI Auto Pilots
Is MNKD in one of our four AI portfolios? Sign in free to see
See how it works→ Details ↓

Earnings

Earnings calendar →
Next report
Nov 5
2026 · Time not announced
Consensus EPS forecast
Members
EPS and revenue estimates
Year-ago EPS
Members
Same quarter last year
Options-implied move
Members
Move priced in by options
Analyst consensus
Strong Buy
Based on 4 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
4firms
4 Buy0 Hold0 Sell
Each firm's latest rating on MNKD in the past 90 days
Average 12-month target
Price targets for MNKDThe average, highest and lowest analyst targets and the target chart are shown to AI Starter and AI Pro members.See plans
Latest rating changes
Chardan CapitalInitiated
Oct 19Buy
Truist SecuritiesMaintained
Oct 7Buy
Cantor FitzgeraldReiterated
Sep 11Buy
Wells FargoTarget lowered
Aug 6Buy
Wells FargoMaintained
Jul 30Buy
DateFirmActionRatingPrice target
Oct 19Chardan CapitalInitiatedBuy
Oct 7Truist SecuritiesMaintainedBuy
Sep 11Cantor FitzgeraldReiteratedBuy
Aug 6Wells FargoTarget loweredBuy
Jul 30Wells FargoMaintainedBuy
Loading…

Seasonality

How MNKD has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2006.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in MNKD in the last 90 days.

Loading…

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether MNKD is in one of them and how their past MNKD trades turned out.

See how it works→ View all auto pilots→
MNKD in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered MNKD in an article yet. Here's the latest on the wider market.

macronewsFriday, October 30, 2026
Binance and Polymarket Hacks Test Crypto's Plumbing, Not Yet Macro
Binance paused withdrawals after a suspected theft of roughly $6 billion, while Polymarket halted trading for an hour after a vendor breach.
Jean Westart · 3 min read
macronewsMonday, October 26, 2026
S&P 500 Sits 2.5% Below Its Record Ahead of the Fed and Big Tech
The S&P 500 slipped 0.47% to 7,623.68, 2.5% below its record, as the Fed meets October 28 and Alphabet, Microsoft and Amazon report.
Marie Crown · 3 min read
macronewsMonday, October 26, 2026
Hightower's Stephanie Link Tells Investors to Add on Volatility
Hightower's Stephanie Link told CNBC's Squawk Box that investors should use market volatility to add to portfolios as earnings season unfolds.
Adam Landser · 2 min read

About Mannkind

MannKind is a biopharmaceutical company based in Danbury, Connecticut. Its products include Afrezza, an inhaled mealtime insulin for adults with diabetes, V-Go, a wearable insulin delivery device, and Furoscix, a home-use treatment for fluid buildup linked to heart failure and chronic kidney disease. Its Tyvaso DPI treatment for pulmonary hypertension is sold by partner United Therapeutics, which pays MannKind royalties. The company makes its inhalable powders and inhalers at its Connecticut facility and sells Afrezza in the United States and through partners in other countries.

Headquarters
Danbury, CT
Founded
1991
Summary based on the company’s 2026 annual report (10-K) ↗